Preclinical models of Parkinson's disease (PD) have been developed using intracerebroventricular (i.c.v.) injection of 6-hydroxydopamine (6-OHDA) to induce neurodegeneration and motor dysfunction.

Researchers from the University of Adelaide have discovered that the earliest days of embryo development have a measurable impact on a person’s future health and ageing.